Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 9/20 | 0.43 |
| ▸ | AURKA | O14965 | 2/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22284167 | 1.00 | MAPK1 (0.43) | MAPK1AURKAPDE2APTGS2TRPV4 | |
| SCHEMBL28335693 | 0.86 | PKM (0.39) | KDM4EALDH1A1FAAH | |
| SCHEMBL22284233 | 0.85 | PIK3CA (0.39) | MAPK1KDM4EALDH1A1FAAH | |
| SCHEMBL20916763 | 0.83 | PTGS2 (0.41) | MAPK1PTGS2KDM4EALDH1A1GAA | |
| SCHEMBL20916766 | 0.83 | PTGS2 (0.41) | MAPK1PTGS2KDM4EALDH1A1GAA | |
| SCHEMBL20920100 | 0.81 | MAPK1 (0.60) | MAPK1AURKA | |
| SCHEMBL20920098 | 0.81 | MAPK1 (0.60) | MAPK1AURKA | |
| SCHEMBL22284303 | 0.80 | ROCK2 (0.42) | MAPK1PDE2APTGS2ALDH1A1 | |
| SCHEMBL30554287 | 0.80 | ROCK2 (0.42) | MAPK1PDE2APTGS2ALDH1A1 | |
| SCHEMBL22284300 | 0.80 | ROCK2 (0.42) | MAPK1PDE2APTGS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110546150-B | Pyrazolyl-containing tricyclic derivatives, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2021-12-21 | — | — | CN | disclosed |
| EP-3699179-A1 | PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2020-08-26 | — | — | EP | disclosed |
| US-20200247815-A1 | PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2020-08-06 | — | — | US | disclosed |
| CN-110546150-A | Pyrazolyl-containing tricyclic derivatives, preparation method and application thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD | 2019-12-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247815-A1 | PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | MAPK1, MAPK11, MAPK14 | MAPK1 1/4885AURKA 2408/4885PDE2A 3605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.